Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 19 01:10PM ET
0.2496
Dollar change
+0.0174
Percentage change
7.49
%
Index- P/E- EPS (ttm)-0.76 Insider Own49.26% Shs Outstand78.36M Perf Week-5.06%
Market Cap19.62M Forward P/E- EPS next Y-0.46 Insider Trans0.00% Shs Float39.88M Perf Month-8.34%
Income-59.49M PEG- EPS next Q-0.14 Inst Own38.77% Short Float0.31% Perf Quarter-22.53%
Sales1.68M P/S11.68 EPS this Y27.14% Inst Trans19.71% Short Ratio0.05 Perf Half Y-51.06%
Book/sh0.75 P/B0.33 EPS next Y9.80% ROA- Short Interest0.12M Perf Year-80.95%
Cash/sh0.96 P/C0.26 EPS next 5Y- ROE- 52W Range0.19 - 1.67 Perf YTD-48.76%
Dividend Est.- P/FCF- EPS past 5Y- ROI-93.39% 52W High-85.05% Beta2.00
Dividend TTM- Quick Ratio6.02 Sales past 5Y209.75% Gross Margin51.19% 52W Low30.54% ATR (14)0.03
Dividend Ex-Date- Current Ratio6.02 EPS Y/Y TTM-167.73% Oper. Margin-3842.97% RSI (14)47.11 Volatility10.27% 12.57%
Employees- Debt/Eq0.23 Sales Y/Y TTM- Profit Margin-3545.47% Recom2.00 Target Price0.65
Option/ShortYes / Yes LT Debt/Eq0.09 EPS Q/Q-118.66% Payout- Rel Volume0.03 Prev Close0.23
Sales Surprise-6.38% EPS Surprise33.33% Sales Q/Q813.41% EarningsFeb 29 AMC Avg Volume2.40M Price0.25
SMA20-5.47% SMA50-10.86% SMA200-55.80% Trades Volume39,976 Change7.49%
Date Action Analyst Rating Change Price Target Change
Nov-18-22Initiated BofA Securities Neutral $2
Oct-25-22Initiated Credit Suisse Outperform $5
Sep-06-22Initiated Cowen Outperform
Feb-29-24 04:01PM
Feb-27-24 02:00AM
Feb-26-24 01:51PM
08:47AM
Feb-21-24 04:05PM
09:55AM Loading…
Jan-15-24 09:55AM
Dec-29-23 08:22AM
Dec-21-23 12:00PM
Dec-18-23 08:00AM
Nov-13-23 09:36AM
Nov-09-23 04:02PM
Oct-19-23 12:27PM
Oct-12-23 08:00AM
Oct-06-23 07:00AM
Sep-21-23 08:00AM
03:03AM Loading…
Sep-15-23 03:03AM
Sep-13-23 01:16PM
08:00AM
Aug-14-23 09:26AM
Aug-11-23 06:43AM
Aug-10-23 04:01PM
Jul-10-23 07:00AM
Jun-08-23 01:20PM
Jun-07-23 07:00AM
May-31-23 07:00AM
May-12-23 11:12AM
May-11-23 04:01PM
May-04-23 02:00AM
May-03-23 04:56PM
07:00AM
08:00AM Loading…
Apr-13-23 08:00AM
Mar-13-23 11:51AM
Mar-08-23 08:32AM
Mar-07-23 04:01PM
Feb-08-23 11:37AM
Feb-06-23 07:00AM
Feb-02-23 07:00AM
Jan-06-23 10:43AM
Jan-05-23 07:00AM
Dec-29-22 02:44PM
Dec-27-22 11:05AM
Dec-01-22 07:00AM
Nov-19-22 07:52AM
Nov-10-22 04:01PM
Nov-01-22 11:53AM
Oct-27-22 07:00AM
Oct-19-22 07:00AM
Sep-21-22 07:00AM
Sep-19-22 07:00AM
Aug-22-22 04:08PM
Akili, Inc. is a digital medicine company, which engages in the development of cognitive treatments through technologies. Its technologies are designed to directly target the physiology of the brain. The company was founded by W. Edward Martucci II and Adam Gazzaley in December 2020 and is headquartered in Boston, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Martucci Walter Edward IIChief Executive OfficerSep 11 '23Sale1.052,3532,4713,150,180Sep 14 08:30 AM
Franklin MatthewPresident & COOSep 11 '23Sale1.051,7281,814753,898Sep 14 08:29 AM
Studer JacquelineChief Legal OfficerSep 11 '23Sale1.051,1301,186348,292Sep 14 08:31 AM
Shanbhag SantoshChief Financial OfficerSep 11 '23Sale1.05830872323,636Sep 14 08:28 AM